Navigation Links
Half of Tamiflu prescriptions went unused during 2009 H1N1 swine flu pandemic, UK sewage study

A new study concludes that approximately half of the prescriptions of Tamiflu during the 2009-10 influenza pandemic went unused in England. The unused medication represents approximately 600,000 courses of Tamiflu at a cost of around 7.8 million to the UK taxpayer. The novel scientific method used in the study could help measure and improve the effectiveness of future pandemic flu strategies.

The finding, published online this week in the open access scientific journal PLOS ONE, comes from the first study of its kind to use sewage water to estimate drug compliance rates, the degree to which a patient correctly follows medical advice to take medication. The study estimated usage of pharmaceuticals from large populations by sampling sewage and recovering the active component of Tamiflu thus measuring drugs that were actually consumed by patients, rather than those that were flushed away without being consumed.

The work was led by scientists at the UK's Centre for Ecology & Hydrology working with colleagues at Uppsala, Linnaeus and Ume Universities, Sweden, and the University of South Bohemia, Czech Republic.

Lead author Dr Andrew Singer, a Chemical Ecologist from the Centre for Ecology & Hydrology, says, "Influenza pandemics are rare, making a study such as this a unique and important window into how people behave during a public health emergency such as a pandemic. This study sheds new light on people's willingness to follow medical advice on antiviral usage. Importantly, this method could be used to monitor how many people take certain kinds of medicine in real time and alert national health authorities to the need for stronger public information campaigns during pandemic emergencies."

The research highlights that despite the central role of antivirals in many nations' influenza pandemic preparedness plans, there remains considerable uncertainty regarding antiviral compliance rates. Poor compliance drains resources by diverting limited antiviral stocks from those who may need it most. Mis-used antivirals can lead to antiviral resistance and represents a significant financial cost and health risk. Previous research on antiviral compliance had focused on small populations, typically fewer than 200, and used survey-based analyses of drug compliance, which can be unreliable.

Dr Singer adds, "Our study was the first compliance study to utilise waste water as an evidence base for whether a population consumed Tamiflu or not. Because of this unique study design, we were able to examine populations orders of magnitude larger than previous studies. One population was just over 6,000 people and the second population was 208,000. Tamiflu gets transformed into the active antiviral only after being consumed, and is released into the sewage with every visit to the toilet. This waste water epidemiology approach is particularly robust for drugs such as Tamiflu and potentially more reliable than some survey based methods of assessing compliance."

Predictions of oseltamivir consumption from Tamiflu recovered in sewage were compared with two sources of national government statistics to derive compliance rates. Scenario and sensitivity analysis indicated an estimated compliance rate between 45-60%, (between 45 to 60 people out of every 100 people who received Tamiflu completed the antiviral course, as prescribed).

Dr Singer says, "With approximately half the collected antivirals going unused, there is a clear need to improve public health messages so that less antiviral is wasted and that the duration and severity of infection is reduced. Furthermore, we feel the waste water epidemiology approach undertaken can potentially help shape future public health messages, making them more timely, targeted, and population sensitive, while potentially leading to less mis- and un-used antiviral, less wastage and ultimately a more robust and efficacious pandemic preparedness strategy."


Contact: Barnaby Smith
Centre for Ecology & Hydrology

Related biology news :

1. 3 distinguished keynote speakers to present during ARVO 2013 Annual Meeting
2. Preventing obesity transmission during pregnancy
3. Female deer take control during the mating season
4. Abuse during childhood linked to uterine fibroids in African-American women
5. Choline supplementation during pregnancy presents a new approach to schizophrenia prevention
6. Chromosome anchors organize DNA during cell division
7. Music with dinner: Whales sing during foraging season, not just while breeding
8. Abuse during childhood linked to adult-onset asthma in African-American women
9. Insight into DNA reprogramming during egg and sperm cell development
10. OHSU study shows that a molecule critical to nerve cells increases drammatically during hypertension
11. New risk factor identified for high blood pressure during pregnancy
Post Your Comments:
(Date:11/19/2015)... 19, 2015  Based on its in-depth analysis of ... BIO-key with the 2015 Global Frost & Sullivan Award ... Sullivan presents this award to the company that has ... needs of the market it serves. The award recognizes ... expands on customer base demands, the overall impact it ...
(Date:11/17/2015)... 17, 2015 Paris from ... --> Paris from 17 th until ... biometrics innovation leader, has invented the first combined scanner in ... same scanning surface. Until now two different scanners were required: ... can capture both on the same surface. This innovation ...
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
Breaking Biology News(10 mins):
(Date:12/1/2015)... SEATTLE , Dec. 1, 2015 Today ... headquarters in Seattle,s South Lake ... northwest corner of Mercer Street and Westlake Avenue North, ... to the Allen Institute for Brain Science and the ... Allen , philanthropist and founder of the Allen Institute. ...
(Date:12/1/2015)... , Dec. 1, 2015 Oxford Finance LLC ... to life sciences and healthcare services companies, today announced ... loan with MDRejuvena, Inc. ("the Company"). Proceeds from the ... development of the Company,s Rejuvaphyl™ and daily skincare products. ... is the MDRejuvena brand of high potency skincare products ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... announces Park NX10 SICM Module, an add-on scanning ion conductance microscopy module to ... of SICM to an AFM. , Park SICM benefits virtually all materials characterization ...
(Date:12/1/2015)... Dec. 1, 2015 Cepheid (Nasdaq: CPHD ... at the Piper Jaffray Healthcare Conference in ... Company is reaffirming its outlook for the fourth quarter ... addition to discussing longer term business model expectations. ... Officer.  "We continue to be the fastest growing company ...
Breaking Biology Technology: